drugset / Trial / NCT00504439

A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects

NCT00504439

Phase 1 Completed 36 enrolled GlaxoSmithKline
RandomizedParallel-groupTreatment

Summary

To assess safety of SB-656933 following repeat dosing for 14 days.

Timeline

Start
2007-06-04
Primary completion
2007-09-06
Completion
2007-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ELUBRIXIN Small molecule 20 mg Oral
Subject ELUBRIXIN Small molecule 50 mg Oral
Subject ELUBRIXIN Small molecule 100 mg Oral
Subject Simvastatin Small molecule 40 mg